The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNFα activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNFα antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNFα activity, such as psoriasis.
